DaVita
DVA
$197.10
+1.12%
DaVita Inc. is the largest provider of dialysis services in the United States, operating over 3,000 facilities globally and treating approximately 280,000 patients annually within the healthcare sector's medical care facilities industry. The company is a dominant market leader with a roughly 35% share of U.S. dialysis clinics, distinguished by a business model heavily reliant on government reimbursement from Medicare and Medicaid, while its profitability is primarily driven by a smaller base of commercial insurance patients. The current investor narrative is intensely focused on the stock's dramatic price surge, which appears driven by a significant corporate or sector-specific catalyst in early February 2026, shifting the debate towards whether the new valuation levels are sustainable given the company's exposure to regulatory reimbursement rates and its mature, steady-growth profile.…
DVA
DaVita
$197.10
Related headlines
Investment Opinion: Should I buy DVA Today?
Rating: Hold. The core thesis is that DaVita's powerful technical breakout and reasonable valuation are counterbalanced by significant fundamental risks and overextended price action, making the risk/reward unattractive for new money at current levels.
Supporting this view, the forward P/E of 11.56x is not excessive for a market leader, and the company generates substantial TTM free cash flow of $1.31B. However, revenue growth is steady but not spectacular at ~10% YoY, and critical profitability metrics are weakening, with gross margin down over 400 basis points year-over-year. The lack of a clear analyst consensus and wide dispersion in ratings (from Underperform to Buy) underscores the high uncertainty and lack of a durable catalyst for further multiple expansion.
The thesis would upgrade to a Buy on a pullback to the $150-$160 range (providing a better margin of safety) or upon clear evidence that margin compression has stabilized. It would downgrade to a Sell if the stock fails to hold above $190 and breaks below its 50-day moving average, signaling the momentum has broken, or if QoQ gross margins fall below 27%. Relative to its own history and the lack of clear peer multiples, the stock appears fairly valued to slightly overvalued given the operational risks it carries.
Sign up to view all
DVA 12-Month Price Forecast
DaVita presents a classic case of technical momentum diverging from mixed fundamentals. The explosive February move suggests a material positive development, but without confirmation, it risks being a speculative overshoot. The company's cash generation and market dominance provide a floor, but margin pressures and leverage create a ceiling. The most likely path is consolidation and volatility as the market seeks clarity. The stance would turn bullish on evidence of sustained margin improvement and a successful hold above $200; it would turn bearish on a breakdown below $175 accompanied by deteriorating quarterly metrics.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on DaVita's 12-month outlook, with a consensus price target around $256.23 and implied upside of +30.0% versus the current price.
Average Target
$256.23
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$158 - $256
Analyst target range
Analyst coverage for DaVita appears limited, with only two analysts providing estimates for revenue and EPS, and no consensus price target or recommendation data provided in the dataset. The institutional ratings list shows sporadic actions from a handful of firms, with the most recent being a 'Buy' reiteration from UBS and an 'Equal Weight' from Barclays in February 2026. The lack of a broad, quantifiable consensus target implies insufficient analyst coverage for a clear sentiment reading. The implications of limited coverage are significant; DaVita, despite its market cap near $10 billion, may be under-followed by the sell-side, which can lead to higher volatility and less efficient price discovery, as evidenced by the recent explosive move. The wide dispersion in analyst actions—ranging from 'Underperform' (B of A Securities) to 'Buy' (UBS)—even among the few firms that do cover it, signals high uncertainty and a lack of strong conviction in a unified direction. This environment increases the importance of investor own due diligence on fundamental drivers like reimbursement rates and operational efficiency.
Bulls vs Bears: DVA Investment Factors
The investment debate for DaVita is intensely polarized between powerful technical momentum and fundamental risks that have not been erased by the price surge. The bull case, currently supported by stronger near-term evidence, rests on a transformative catalyst (implied by the February breakout), robust cash generation for buybacks, and a valuation that remains reasonable relative to history. The bear case warns of unsustainable volatility, deteriorating margins, and deep-seated structural risks from leverage and government dependence. The single most important tension is whether the recent parabolic move is pricing in a permanent improvement in the company's regulatory/payer outlook or is a speculative overshoot that will correct sharply when the fundamental margin pressures reassert themselves.
Bullish
- Massive Technical Breakout & Momentum: The stock has surged 65.21% over 6 months and 32.53% in the past month, breaking decisively from a consolidation range. This powerful uptrend, with the price at 98% of its 52-week high, signals strong investor conviction and a major positive catalyst, likely related to reimbursement or regulatory news.
- DaVita generates robust cash flow, with TTM FCF of $1.31B, funding aggressive shareholder returns. In Q4 2025 alone, the company executed $759M in share repurchases, a clear commitment to enhancing shareholder value and supporting the stock price.
- Reasonable Valuation Despite Price Surge: Despite the parabolic price move, the forward P/E of 11.56x is below the trailing P/E of 13.10x and is not at historical highs (e.g., 18.63x in Q1 2025). This suggests earnings growth is keeping pace with the rally, preventing extreme overvaluation on an earnings basis.
- Dominant Market Position & Steady Growth: As the U.S. market leader with ~35% share, DaVita benefits from scale in a necessary healthcare service. Revenue grew 9.87% YoY in Q4 2025 to $3.62B, demonstrating a stable, utility-like growth profile that is resilient in most economic conditions.
Bearish
- Extreme Price Volatility & Overextension Risk: The stock has more than doubled from its 52-week low of $101, with a recent 1-month surge of +32.53%. Trading at 98% of its all-time high, it is vulnerable to a sharp technical pullback, especially given its historically low beta of 0.836, which the recent move has violently departed from.
- Margin Compression Threatens Profitability: Gross margin compressed to 28.28% in Q4 2025 from 32.46% in Q4 2024. This pressure, likely from payer mix and cost inflation, directly threatens the core profit engine, as nearly all profits come from a small base of commercial insurance patients.
- High Financial Leverage & Negative Equity: The company has a highly leveraged capital structure with a debt-to-equity ratio of -23.12 due to negative shareholder equity from aggressive buybacks. This increases financial risk and limits strategic flexibility, especially in a rising interest rate environment.
- Regulatory & Reimbursement Concentration Risk: Approximately two-thirds of U.S. sales rely on government (Medicare/Medicaid) reimbursement rates. Any adverse changes to these rates, which are subject to political and budgetary pressures, would have an outsized impact on revenue and the fragile profit model.
DVA Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 1-year price change of +41.04% and a 6-month surge of +65.21%. As of the latest close at $198.66, the price is trading at approximately 98% of its 52-week high of $202.69, positioning it near absolute highs which signals strong momentum but also raises concerns about potential overextension and vulnerability to a pullback. The prevailing trend shifted decisively from a period of consolidation and weakness in January 2026 to a parabolic move beginning in early February, with the price more than doubling from its 52-week low of $101.00. Recent short-term momentum is exceptionally strong and aligns with the longer-term trend, with a 1-month price change of +32.53% and a 3-month change of +31.80%. This acceleration is starkly illustrated by the price vaulting from around $111 on February 2nd to over $149 by February 13th, a move that represents a dramatic breakout from the previous trading range. The stock has demonstrated significant relative strength, outperforming the SPY by 27.04 percentage points over the past month, indicating it is driven by strong idiosyncratic catalysts rather than broad market moves. Key technical support is now viewed at the pre-breakout zone near the 52-week low of $101.00, though a more immediate support level may have formed around the $140-$150 range following the initial surge. Immediate resistance is at the 52-week high of $202.69; a decisive breakout above this level could signal a continuation of the bullish impulse, while a failure and reversal would suggest a double-top formation. With a beta of 0.836, the stock has historically been less volatile than the market, but the recent explosive move represents a dramatic departure from this characteristic, introducing heightened near-term volatility risk for traders.
Beta
0.84
0.84x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$101-$203
Price range past year
Annual Return
+44.2%
Cumulative gain past year
| Period | DVA Return | S&P 500 |
|---|---|---|
| 1m | +31.3% | +6.0% |
| 3m | +26.1% | +10.0% |
| 6m | +64.7% | +10.4% |
| 1y | +44.2% | +28.4% |
| ytd | +72.1% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DVA Fundamental Analysis
DaVita's revenue trajectory shows steady, single-digit growth, with Q4 2025 revenue of $3.62 billion representing a 9.87% year-over-year increase. Analyzing the sequential quarterly data from 2025, revenue grew from $3.22 billion in Q1 to $3.62 billion in Q4, indicating consistent top-line expansion. The business is entirely driven by its U.S. Dialysis and Related Lab Services segment, which generated $10.12 billion over an unspecified period, confirming the lack of segment diversification. This growth trend supports the company's stable, utility-like profile in a necessary healthcare service, though it is not indicative of hyper-growth. The company is profitable, with Q4 2025 net income of $234.22 million and a net margin of 6.47%. Gross margin for the quarter was 28.28%, while the operating margin stood at 15.24%. Comparing margins year-over-year reveals some compression; for instance, the Q4 2025 gross margin of 28.28% is lower than the 32.46% reported in Q4 2024. This margin pressure is a critical focus, likely relating to the mix of government versus commercial payers and ongoing cost inflation, which directly impacts the core investment thesis around profitability stability. DaVita's balance sheet shows a highly leveraged structure with a negative debt-to-equity ratio of -23.12, a result of negative shareholder equity, which is a known characteristic of the company due to significant share buybacks. However, the company generates robust cash flow, with trailing twelve-month free cash flow of $1.31 billion and an operating cash flow of $540.73 million in Q4 2025. The current ratio of 1.29 indicates adequate short-term liquidity. The substantial free cash flow, which funds aggressive share repurchases (evidenced by $759 million in buybacks in Q4 alone), is a cornerstone of its financial strategy and shareholder returns, offsetting concerns from the unconventional capital structure.
Quarterly Revenue
$3.6B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.28%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DVA Overvalued?
Given DaVita's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 13.10x, while the forward PE is lower at 11.56x, based on estimated EPS of $18.12. The discount of the forward PE suggests the market anticipates earnings growth, which aligns with analyst estimates for the coming year. Comparing DaVita's valuation to industry averages is challenging as specific sector multiples are not provided in the data. However, a trailing PE of 13.10x for a stable, cash-generative healthcare services company appears reasonable on an absolute basis, especially when considering its market leadership position. The more telling comparison may be against its own historical range to assess if the recent price surge has led to overvaluation. Historically, DaVita's PE ratio has fluctuated significantly. The current trailing PE of 13.10x sits well below the extreme highs seen in recent quarters, such as 18.63x in Q1 2025 and 15.93x in Q3 2025, and is more aligned with levels from late 2024 (11.77x in Q4 2024). This historical context suggests that despite the massive price appreciation, the valuation on an earnings basis has not reached historical peaks, as earnings have likely grown in tandem. The stock is not near the top of its own historical PE band, which may provide some valuation support if earnings forecasts are met.
PE
13.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on DaVita's precarious profitability model and leveraged balance sheet. Gross margin compression from 32.46% to 28.28% year-over-year highlights sensitivity to payer mix and cost inflation, directly endangering the profits derived from commercial insurers. The company's negative shareholder equity and debt-to-equity of -23.12, a result of funding massive buybacks with debt, create a fragile capital structure that could struggle if free cash flow (TTM $1.31B) decelerates. Furthermore, the business lacks diversification, with 100% of revenue from U.S. Dialysis services, creating extreme concentration risk.
Market & Competitive Risks are elevated by the stock's recent performance. The 65% surge in 6 months has pushed the stock to 98% of its 52-week high, creating significant valuation compression risk if the catalyst fueling the move disappoints. While the forward P/E of 11.56x appears reasonable, the stock's low beta of 0.836 has been shattered by recent volatility, indicating it is now trading on idiosyncratic news, which can reverse quickly. The company operates in a politically sensitive sector, perpetually exposed to regulatory headwinds aiming to reduce government healthcare spending, which could pressure the dominant Medicare/Medicaid reimbursement stream.
Worst-Case Scenario involves a one-two punch of regulatory pressure and a failed growth narrative. A negative update on Medicare reimbursement rates, combined with a quarterly earnings miss that confirms margin erosion, could trigger a rapid de-rating. This could be exacerbated by a broader market downturn, forcing a unwind of momentum-driven positions. The realistic downside could see the stock retrace a significant portion of its gains, potentially falling back toward the $140-$150 support zone from the initial breakout, representing a -25% to -30% decline from the current ~$198 level, or even testing the 52-week low of $101 in a severe crisis, a -49% drawdown.
FAQ
The key risks are, in order of severity: 1) Regulatory/Reimbursement Risk: Two-thirds of revenue depends on government rates, which are politically vulnerable. 2) Profit Margin Risk: Gross margin fell to 28.28% from 32.46% YoY; further erosion would cripple profits from commercial payers. 3) Financial Leverage Risk: Negative shareholder equity and high debt (D/E: -23.12) limit flexibility and amplify downside. 4) Technical & Sentiment Risk: The stock is up 65% in 6 months and prone to a sharp reversal if the unnamed catalyst disappoints, as seen in its low analyst coverage and mixed ratings.
Our 12-month outlook presents three scenarios. The Base Case (55% probability) sees the stock consolidating between $175 and $195 as initial excitement fades and steady growth continues amid margin challenges. The Bull Case (25% probability), targeting $215-$230, requires confirmation of a positive regulatory shift and margin stabilization. The Bear Case (20% probability), with a target of $125-$150, involves a failed catalyst and worsening fundamentals triggering a de-rating. The Base Case is most likely, implying a modest downside from the current ~$198 price, with high volatility expected throughout the year.
Based on earnings, DVA appears fairly valued. Its forward P/E of 11.56x is below its trailing multiple and not at historical extremes, suggesting the market is pricing in modest growth. However, valuation must be considered in context: the price is at 98% of its 52-week high following a parabolic move, which introduces technical overextension risk. Furthermore, the compression in gross margin (down over 4 percentage points YoY) means the 'E' in P/E is under pressure. The market is thus valuing DVA as a stable cash generator but is also demanding a discount for its operational risks and leveraged balance sheet.
DVA is a high-risk, high-volatility proposition at its current price near all-time highs. For investors who already own it, holding may be prudent to see if the catalyst materializes. For new buyers, the risk/reward is unattractive after a 65% 6-month surge. It could be a good buy for very tactical traders on a significant pullback (e.g., to the $150s) that provides a margin of safety against the very real risks of margin compression and regulatory pressure. The lack of analyst consensus underscores the difficulty of making a clear call.
DVA is primarily suitable for a medium- to short-term tactical horizon given its current state. The dramatic price move and unresolved catalyst make it a trading vehicle in the near term (3-12 months). For a long-term investor, the structural risks of government dependence and leverage are significant, though the company's market dominance provides some durability. A minimum holding period should be through the next 2-3 earnings cycles to assess whether margin trends are improving. The stock does not pay a dividend, eliminating an income component for long-term holders. Given the beta of 0.836 (historically), it has been less volatile than the market, but recent action contradicts this, so investors must be prepared for sharp swings.